DIA 2024 Global Annual Meeting

Attending this event?

DIA 2024 Global Annual Meeting

arrow_back View All Dates

8:00am PDT

#209: Leveraging New Meeting Opportunities in PDUFA VII: Experiences with Type D and INTERACT Room 11AB #210: Digital Biomarkers as Clinical Endpoints: The Road to Regulatory Acceptability Room 6B #211: PMDA Town Hall Room 15AB

10:00am PDT

#228: Access Consortium and Project Orbis: Experiences from Industry and Regulatory Authorities and Recommendations for Improvement Room 16AB

11:00am PDT

#231 CH: Quality in Focus: Diethylene and Ethylene Glycol Challenges Content Hub Sails Pav #233 RT: Roundtable Discussion: The State of Real-World Evidence for Regulatory Decision-Making - Views from FDA, EMA, and PMDA Room 6E

1:15pm PDT

#248: The Evolving Role of Artificial Intelligence in the Medicinal Product Lifecycle Room 6F #253: Platform Technology Designation: Opportunities and Challenges for Implementation Room 6B #254: FDA Rare Disease Town Hall Room 6A #245: The European Clinical Trials Environment Under the Accelerating Clinical Trials (ACT EU) Initiative: Two Years On Room 5AB #255: International Harmonization to Support Pharmaceutical Quality and Lifecycle Management Room 6C

2:15pm PDT

#258 RT: Roundtable Discussion: Supporting Regulatory Convergence and Reliance Through a Pharmaceutical Quality Knowledge Management Capability Ballroom 20 BC/ Zone 2

3:15pm PDT

#264: Enhancing Adoption of Innovative Approaches in Clinical Trials Room 6A #272: This is Your Pilot Speaking: The Journey from Regulatory Pilot Program Innovation to Routine Practice Room 6F #273: How to Provide Necessary Medicinal Products to Children? Room 17AB #267: Evolution of Electronic Product Information in LATAM: Challenges and Opportunities to Improve the Value of Healthcare Room 11AB #274: Regulatory Policy Roundtable: Pharmaceutical Quality, Generics, Innovative Medicines Room 6C

4:30pm PDT

#285: Remote Regulatory Assessments: Examining Another Tool in the FDA Regulatory Toolbox Room 16AB #286: Recent Evolution of the Accelerated Approval Pathway: Impacts on Use and Implementation Room 6A #287: ANVISA Town Hall Room 14AB